VivoSeq
Oncology

Head and Neck Squamous Cell Carcinoma (HNSCC)

12

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Head and Neck Squamous Cell Carcinoma (HNSCC) is an emerging landscape with 12 programs across 6 companies. The most active players are Boehringer Ingelheim, Imclone, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1I

Imclone

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Regeneron logo

Regeneron

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2G

Glycyx Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Monoclonal antibody

8 of 10 classified programs — the dominant modality here.

20%ALL OTHERSSmall molecule220%

Monoclonal antibody leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 79% of 14 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Completed1 · 20%
Active, not recruiting1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

A Phase I/IIa Clinical Trial to Investigate the Safety, Immunogenicity and Efficacy of BVAC-E6E7 in Subjects With HPV Type 16 and/or 18 Positive Unresectable Recurrent or Metastatic Head
Recruiting·CCellid Co., Ltd.·Preclinical·NCT06797986·37 enrolled
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05249426·48 enrolled
Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression
Recruiting·Regeneron logoRegeneron·Phase 2·NCT06769698·120 enrolled
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer
Active, not recruiting·—·Phase 2·NCT04080804·80 enrolled
A Phase I/II, Open-Label, Study to Assess the Safety, Tolerability, and Efficacy of Axelopran Administered With Standard of Care Pembrolizumab in Recurrent/Metastatic HNSCC Patients Taking Opioids to Control Cancer Pain
Not yet recruiting·GGlycyx Therapeutics·Preclinical·NCT07662720·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)